Insider Selling: DexCom, Inc. (NASDAQ:DXCM) COO Sells 14,076 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM - Get Free Report) COO Jacob Steven Leach sold 14,076 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares of the company's stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Jacob Steven Leach also recently made the following trade(s):

• On Wednesday, January 29th, Jacob Steven Leach sold 2,634 shares of DexCom stock. The stock was sold at an average price of $86.91, for a total value of $228,920.94.

DexCom Stock Performance

Shares of DXCM stock traded down $0.65 on Tuesday, reaching $70.70. The stock had a trading volume of 2,603,968 shares, compared to its average volume of 3,881,061. The stock has a market cap of $27.63 billion, a P/E ratio of 49.44, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. The company has a 50 day simple moving average of $83.82 and a 200 day simple moving average of $76.94.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Remove Ads

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on DXCM shares. Morgan Stanley raised their price objective on DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a research report on Friday, February 14th. Baird R W raised DexCom from a "hold" rating to a "strong-buy" rating in a research report on Thursday, January 16th. Citigroup raised their price objective on DexCom from $101.00 to $104.00 and gave the company a "buy" rating in a research report on Tuesday, March 4th. Canaccord Genuity Group raised their price objective on DexCom from $99.00 to $103.00 and gave the company a "buy" rating in a research report on Friday, February 14th. Finally, Robert W. Baird raised DexCom from a "neutral" rating to an "outperform" rating and raised their price objective for the company from $86.00 to $104.00 in a research report on Thursday, January 16th. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $99.82.

Hedge Funds Weigh In On DexCom

Several institutional investors and hedge funds have recently bought and sold shares of DXCM. Jennison Associates LLC lifted its position in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company's stock valued at $464,782,000 after purchasing an additional 6,544,102 shares in the last quarter. Norges Bank purchased a new position in DexCom during the fourth quarter valued at $385,367,000. Congress Asset Management Co. lifted its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company's stock valued at $105,529,000 after purchasing an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD purchased a new position in DexCom during the fourth quarter valued at $96,507,000. Finally, Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% during the third quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company's stock valued at $190,532,000 after acquiring an additional 876,739 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.